PAUL OFFIT: Well we knew that the AstraZeneca product, the UK product, which is a similar platform to the J&J product, had a problem in Europe, where roughly one per 250,000 people who got that vaccine could have these kinds of blood clots, meaning so-called central venous sinus thrombosis, or said another way, a blood clot in the brain. And what the public is to think about this news from those agencies.ĭR. So I guess just start with talking us through what you understand from the FDA and CDC statement this morning. Offit, thank you so much for jumping on this morning. He's the director of the Vaccine Education Center at Children's Hospital of Philadelphia. Well let's bring in someone who's an expert in this field for a little bit more color on today's developments, what we do and do not know so far. And while it's too early to tell if there is similarities because of similar platforms, health experts are watching this very closely right now. We know that similar concerns did spur a halt of the vaccine for AstraZeneca in Europe. But as it stands right now that's as much information as we do have. We're going to hear more from the FDA at around 10 o'clock today. So we heard from the FDA this morning that they're recommending a halt on the use of Johnson & Johnson's vaccine, as you noted, on reports of six blood clots out of more than 6.8 million doses that have already been administered. Yahoo Finance health reporter Anjalee Khemlani joins us now with the details on the FDA'S statement this morning. Let's begin this morning with that breaking news on Johnson & Johnson's COVID vaccine. Paul Offit, Children’s Hospital of Philadelphia (CHOP) director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases, joins Yahoo Finance to discuss the latest setback in vaccinations.
0 Comments
Leave a Reply. |